Pharma and Healthcare Companies to Face Continued Margin Pressure: HDFC Securities

Why It Matters

The outlook signals sustained top‑line growth but tightening profitability, prompting investors to reassess valuation and companies to prioritize cost control and product diversification.

Key Takeaways

• Pharma sales projected 10% YoY growth, driven by India market
• US formulations down 5% QoQ due to pricing pressure
• EBITDA margins expected to fall 110 bps YoY
• Hospital segment forecast 15% YoY growth from occupancy and capacity
• Retail pharmacy chains Medplus, Apollo HealthCo target >20% YoY growth

Pulse Analysis

The Indian pharmaceutical landscape is entering a phase of balanced expansion, according to HDFC Securities' latest brokerage report. While the sector is set to achieve 11% sales growth and a modest 6% rise in EBITDA, the underlying dynamics reveal a split between robust domestic demand and headwinds abroad. India’s chronic‑care segment is leading the charge with a 16% surge, and the hospital business is buoyed by higher occupancy rates and new bed capacity, positioning the market for steady revenue inflows.

However, margin pressure remains a central concern. The report highlights a 110‑basis‑point contraction in pharma EBITDA margins, driven by rising input costs, persistent pricing erosion in the United States, and the absence of high‑margin products like gRevlimid. The US generics market is expected to shrink quarter‑over‑quarter, further eroding profitability. Coupled with steady R&D spend and elevated SG&A outlays, these factors compel companies to tighten cost structures and accelerate the rollout of higher‑margin specialty drugs such as gJynarque, gSpiriva, and gMyrbetriq.

For investors, the mixed outlook underscores the importance of segmental diversification. Diagnostic and retail pharmacy units are projected to post 15%‑plus growth, with Medplus and Apollo HealthCo targeting double‑digit YoY increases, offering potential offset to pharma margin compression. Hospital operators may face pressure from a shifting international payor mix, but capacity expansions could sustain top‑line momentum. Stakeholders should monitor input‑cost trends, US pricing dynamics, and the rollout of specialty portfolios as key levers influencing future earnings trajectories.